(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Despite half of lung cancers being diagnosed in people aged 75 or older, randomized evidence on screening outcomes in this age group is limited. Most national lung cancer screening programs, including the UK’s, stop at age 74. The U.S. Preventive ...

(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  – Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Video-assisted thoracoscopic surgery (VATS) is currently the most common approach to perform pulmonary lobectomy in early-stage lung cancer. Advantages include reduced pain, fewer complications, faster recovery and improved quality-of-life. The adoption of VATS lobectomy ...

(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  – Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile. Despite complete surgical resection (R0), early-stage NSCLC carries a substantial risk of recurrence and remains a leading cause of cancer-related ...

(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  — Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation durvalumab alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Consolidation durvalumab improves survival ...

  In Europe, almost one in 10 people over 70 suffers from dementia, and this figure could even triple by 2050 due to rising life expectancy. Over time, those affected lose everything that makes them who they are, including their memory and their ability to go about their everyday lives. Many also suffer from physical deterioration. In an advanced stage of the disorder, dementia patients generally require comprehensive care. Now, the first drugs have emerged that can slightly slow down disease progression in the early stages of Alzheimer’s – ...

New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. Pain management is essential during cancer care, but prescription opioid practices associated with cancer treatment may lead to unsafe long-term opioid use and adverse outcomes such as opioid use disorder and opioid overdose. To assess the ...

Black adolescents with mental distress are less likely to use mental health services than their White peers, and Black girls are the least likely to access care, according to new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241733. “Adolescence is a crucial developmental stage and a critical period for onset of mental health problems,” writes Mercedes Sobers, a PhD candidate in epidemiology at the Dalla Lana School of Public Health, University of Toronto and research coordinator at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, ...

Canada must enact strong, effective legislation to protect youth from gambling advertising. Minors are suffering harms from problem gambling despite age restrictions, argue authors in an editorial in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251227 . Since 2021, ads for sports betting have saturated sports broadcasts, constantly viewed by children. Gambling is normalized as a natural part of spectatorship at a young age. Even before single-game sports betting was legalized, a 2019 survey of Canadian students in grades 7–12 found about 4% of students ...

First-in-Human Trial Shows Promising Results for DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer (Barcelona, Spain Sunday, September 7, 2025 at 4:45 PM CEST / UTC +2) — A first-in-human Phase 1 study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC).  The results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). According to the International Agency for Research on Cancer, ...

(Barcelona, Spain. September 7, 2025 at 4:45 PM CEST / UTC +2 )--Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. New data from the Phase 2 IDeate-Lung01 trial in 137 patients who had received ≥1 prior line of platinum-based chemotherapy showed a confirmed objective response rate (ORR) of ...

Research Highlights: Children who had higher blood pressure at age 7 were more likely to die early from cardiovascular disease by their mid-50s. The risk was highest for children whose blood pressure measurements were in the top 10% for their age, sex and height. Both elevated blood pressure (90-94th percentile) and hypertension (≥95th percentile) were linked with about a 40% to 50% higher risk of early cardiovascular death in adulthood. Researchers said their findings show why it’s important to regularly check children’s blood pressure and to help them develop heart-healthy habits early that can help lower their ...

Research Highlights: Use of an AI voice agent to prompt self-reported blood pressure readings helped to improve accuracy of blood pressure measures and patient outcomes in a group of majority ages 65 and older patients with high blood pressure. The study’s findings demonstrate how integrating AI into care can help to improve home blood pressure monitoring and completion rates, which can lead to improved quality outcomes for patients. Note: The study featured in this news release is a research abstract. Abstracts presented at the American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published ...

About The Study: In a large sample of U.S. children born between 1959 and 1966, higher blood pressure (BP) at age 7 was associated with greater risk of premature cardiovascular disease (CVD) mortality. These findings build upon prior research that linked childhood systolic BP with fatal CVD in young adulthood, but that sample had a follow-up duration through a mean age of only 46 years. This study extends that work with follow-up into the mid-50s and demonstrated consistency in the magnitude of the associations within siblings, which mitigates concerns regarding unmeasured confounding due to shared family or lifestyle characteristics. Corresponding ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy.  ROS1-positive NSCLC occurs in approximately 1–2% of all NSCLC cases. The results from the Phase ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase 3 E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). The trial, conducted within the ALCHEMIST clinical trials program, ...

Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs). Results from the global Phase 3 HARMONi trial were presented today by Jonathan ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC). These findings, presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer, support osimertinib plus chemotherapy as a new standard-of-care ...

Contact: Chris Martin, MPH IASLC Media Relations cmartin@davidjamesgroup.com (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) – New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations. The results were presented by Dr. Jie Wang, National Cancer Center, ...

Contact: Chris Martin, MPH/IASLC Media Relations/cmartin@davidjamesgroup.com (Barcelona, Spain — September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Iza-bren is a first-in-class EGFR x HER3 bispecific ADC linked to a novel topoisomerase I inhibitor payload (Ed-04). The drug was evaluated ...

Iza-Bren in combination with Osimertinib Shows 100% Response Rate in EGFR-Mutated NSCLC, Phase II Study Finds Barcelona, Spain (September, 2025) —A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). Iza-bren is a first-in-class ADC combining EGFR and HER3 targeting with a topoisomerase I inhibitor payload. The study tested iza-bren at multiple ...

(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). The COMPEL study is a global, randomized, double-blind trial, in which adult patients with non-CNS progression on first-line osimertinib were randomized 1:1 to receive either osimertinib ...

(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease. These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). The study assessed HRQoL by nodal status and surgical outcomes using patient-reported outcome (PRO) measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual ...

(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population. The study, conducted by the University of Illinois Hospital & Clinics, (UI Health), the academic health enterprise of the University of Illinois Chicago (UIC), highlights Sybil’s strong performance in a real-world clinical setting with racially and socioeconomically ...

Research Highlights: Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have uncontrolled high blood pressure. The analysis also found that baxdrostat lowered the loss of albumin in the urine, which is a marker of kidney and cardiovascular risk, by 55% compared to placebo, suggesting that this medication may help delay the progression of kidney disease . These findings suggest the potential for baxdrostat to improve longer-term health outcomes like kidney and ...

  The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively infect and destroy tumor cells, while simultaneously stimulating anti-tumor immune responses. The latest advancements in genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced patient quality of life.   By combining OVs with cellular immunotherapy, immune checkpoint inhibitors, cancer vaccines, cytokines, and bi- or tri-specific T cell engagers, researchers have developed innovative ...